📣 VC round data is live. Check it out!

Caribou Biosciences Valuation Multiples

Discover revenue and EBITDA valuation multiples for Caribou Biosciences and similar public comparables like Context Therapeutics, Precision BioSciences, MediWound, Elicio Therapeutics and more.

Caribou Biosciences Overview

About Caribou Biosciences

Caribou Biosciences Inc is a clinical-stage Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) biopharmaceutical company dedicated to transforming the lives of patients with devastating diseases by applying its novel CRISPR platform, CRISPR hybrid RNA-DNA (chRDNA), toward the development of next-generation, genome-edited cell therapies. The company operates and manage business as one reportable operating segment, which is the business of developing a pipeline of allogeneic CAR-T and CAR-NK cell therapies. Geographically, it operates in United States and Rest of the World, of which United States derives maximum revenue.


Founded

2011

HQ

United States

Employees

147

Financials (LTM)

Revenue: $16M
EBITDA: ($140M)

EV

$122M

Valuation Multiples

Start free trial

Valuation Multiples for 15K+ Public Comps

AdidasAirbnbAmazonCiscoCoca-ColaDellDropboxIBMIntelMcDonaldsNikeNVIDIASamsungSpotifyTeslaToyota
Browse Valuation Multiples

Caribou Biosciences Financials

Caribou Biosciences reported last 12-month revenue of $16M and negative EBITDA of ($140M).

In the same LTM period, Caribou Biosciences generated $16M in gross profit, ($140M) in EBITDA losses, and had net loss of ($138M).

Revenue (LTM)


Caribou Biosciences P&L

In the most recent fiscal year, Caribou Biosciences reported revenue of $11M and EBITDA of ($133M).

Caribou Biosciences is unprofitable as of last fiscal year, with EBITDA margin of (1188%) and net margin of (1327%).

See analyst estimates for Caribou Biosciences
LTMLast FY202320242025202620272028
Revenue$16M$11M$34M$10M$11M
Gross Profit$16M$11M
Gross Margin100%100%
EBITDA($140M)($133M)($113M)($163M)($133M)
EBITDA Margin(889%)(1188%)(326%)(1628%)(1188%)
EBIT Margin(885%)(1220%)(337%)(1667%)(1220%)
Net Profit($138M)($148M)($102M)($149M)($148M)
Net Margin(876%)(1327%)(296%)(1492%)(1327%)

Financial data powered by Morningstar, Inc.

Caribou Biosciences Stock Performance

Caribou Biosciences has current market cap of $212M, and enterprise value of $122M.

Market Cap Evolution


Caribou Biosciences' stock price is $2.14.

Caribou Biosciences share price increased by 13.2% in the last 30 days, and by 101.9% in the last year.

Caribou Biosciences has an EPS (earnings per share) of $-1.49.

See more trading valuation data for Caribou Biosciences
EVMarket CapPrice 1DPrice 1MPrice 3MPrice 12MEPS
$122M$212M0.9%13.2%16.5%101.9%$-1.49

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.

Start Free Trial

Caribou Biosciences Valuation Multiples

Caribou Biosciences trades at 7.7x EV/Revenue multiple, and (0.9x) EV/EBITDA.

See NTM and 2027E valuation multiples for Caribou Biosciences

EV / Revenue (LTM)


Caribou Biosciences Financial Valuation Multiples

As of May 15, 2026, Caribou Biosciences has market cap of $212M and EV of $122M.

Caribou Biosciences has a P/E ratio of (1.5x).

LTMLast FY202320242025202620272028
EV/Revenue7.7x10.9x3.5x12.2x10.9x
EV/EBITDA(0.9x)(0.9x)(1.1x)(0.7x)(0.9x)
EV/EBIT(0.9x)(0.9x)(1.0x)(0.7x)(0.9x)
EV/Gross Profit7.7x10.9x
P/E(1.5x)(1.4x)(2.1x)(1.4x)(1.4x)
EV/FCF(1.1x)(1.2x)(0.8x)(1.1x)

Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Verified Caribou Biosciences Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.

FactSetMorningstar
Start Free Trial

Caribou Biosciences Margins & Growth Rates

Caribou Biosciences grew revenue by 112% and EBITDA by 15% in the last fiscal year.

In the most recent fiscal year, Caribou Biosciences reported EBITDA margin of (1188%) and net margin of (1327%).

See estimated margins and future growth rates for Caribou Biosciences

Caribou Biosciences Margins

Last FY202420252026202720282029
Gross Margin100%100%
EBITDA Margin(1188%)(1628%)(1188%)(648%)
EBIT Margin(1220%)(1667%)(1220%)(542%)
Net Margin(1327%)(1492%)(1327%)(512%)
FCF Margin(1007%)(1448%)(1007%)

Caribou Biosciences Growth Rates

FY+1/FY23/2424/2525/2626/2727/2828/29
Revenue Growth112%(71%)12%112%
Gross Profit Growth112%
EBITDA Growth15%45%(19%)15%
EBIT Growth(6%)44%(18%)(6%)
Net Profit Growth(18%)46%(1%)(18%)
FCF Growth38%(22%)

Data powered by FactSet, Inc. and Morningstar, Inc.

Caribou Biosciences Operational KPIs

Caribou Biosciences' revenue per employee in the last FY averaged $0.1M, while opex per employee averaged $1.0M for the same period.

Caribou Biosciences' Rule of 40 is (537%) (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

Caribou Biosciences' Rule of X is (369%) (created by Bessemer, Rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

Access forward-looking KPIs for Caribou Biosciences
LTMLast FY202320242025202620272028
Rule of 40(831%)(537%)
Bessemer Rule of X(744%)(369%)
Revenue per Employee$0.1M
Opex per Employee$1.0M
S&M Expenses to Revenue49%109%109%
G&A Expenses to Revenue232%340%112%465%340%
R&D Expenses to Revenue691%981%325%1302%981%
Opex to Revenue1320%437%1767%1320%

Data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 230+ Verticals

Caribou Biosciences Competitors

Caribou Biosciences competitors include Context Therapeutics, Precision BioSciences, MediWound, Elicio Therapeutics, Sol-Gel Technologies, Keros Therapeutics, Binex, Atrium Therapeutics, Silence Therapeutics and Pyridam Farma.

Most Caribou Biosciences public comparables operate across Biopharmaceuticals, BioTech and DeepTech.

EV/RevenueEV/EBITDA
Last FYLTM2027ELast FYLTM2027E
Context Therapeutics(4.0x)
Precision BioSciences3.3x3.9x(2.7x)(2.2x)
MediWound10.1x8.6x(8.4x)(6.8x)
Elicio Therapeutics(5.6x)
Sol-Gel Technologies10.0x(26.1x)
Keros Therapeutics(0.2x)(0.3x)(0.8x)
Binex2.4x2.2x31.8x73.6x
Atrium Therapeutics(3.2x)(5.1x)0.8x

This data is available for Pro users. Sign up to see all Caribou Biosciences competitors and their valuation data.

Start Free Trial

Caribou Biosciences Funding History

Before going public, Caribou Biosciences raised $168M in total equity funding, across 4 rounds.


Caribou Biosciences Funding Rounds

DateStageRaised FromRaisedValuationRev. MultipleDeal Summary
Mar-21Series CFarallon Capital Management; PFM Health Sciences; Ridgeback Capital$115MCaribou Biosciences, Inc. (NASDAQ: CRBU) is a biotechnology company specializing in allogeneic CAR-T cell therapies using its proprietary chRDNA CRISPR genome-editing technology. Founded in 2014 from research by Dr. Jennifer Doudna and Dr. Luciano Marraffini at UC Berkeley, the company develops off-the-shelf cell therapies for hematologic malignancies and solid tumors, addressing limitations of autologous CAR-T like manufacturing time and costs. Lead programs include vispa-cel (CB-010) for relapsed/refractory B-cell non-Hodgkin lymphoma (with FDA RMAT, fast track, orphan designations) and CB-011 for multiple myeloma (fast track, orphan designations). The funding supported advancement of its CRISPR-edited allogeneic CAR-T pipeline. The company went public later in 2021, enabling public financial reporting; as of recent data, market cap is around $127-180 million with ongoing clinical development focus on vispa-cel and CB-011 after exiting early programs and workforce reductions. For the full year 2021, Caribou reported revenue of $9.6 million USD, with net loss of $66.9 million USD; this figure aligns temporally with the March round. Earlier years showed 2020 revenue of $12.4 million and 2019 at $5.8 million. Quarterly breakdowns post-IPO include higher figures like $23.7 million in 2023Q3, but 2021 annual revenue provides the closest metric near the round date. Competitive context positions Caribou in the allogeneic CAR-T space, emphasizing advantages like single-dose regimens, lower manufacturing costs, broader access, and multiplex editing over autologous CAR-T and bispecifics.
May-16Series BAliment Capital; Anterra Capital; F-Prime; Genoa Ventures; Heritage Group; Maverick Ventures; Mission Bay Capital; Novartis; Shu Duan$30MCaribou Biosciences is a biotechnology company in the healthcare sector, publicly traded as CRBU, with recent quarterly revenues such as 2.0 million USD in 2024Q3 and yearly revenue of 34.5 million USD in 2023, alongside consistent net losses.
Mar-15Series AF-Prime; Genoa Ventures; Jennifer Doudna; Mission Bay Capital; Novartis; The Howard Hughes Medical Institute; U.C. Berkeley$11MCaribou Biosciences, a developer of CRISPR-Cas9 technologies for precision cell engineering, closed an $11 million Series A financing round on April 2, 2015. Investors included Fidelity Biosciences, Novartis, Mission Bay Capital, 5AM Ventures, and an undisclosed strategic partner, with Jennifer Doudna, co-founder and Howard Hughes Medical Institute investigator and U.C. Berkeley professor, also participating as an investor. The funding aimed to accelerate deployment of the company's proprietary CRISPR-Cas9-based cell engineering platform for therapeutic research and development, agricultural biotechnology, and industrial biotechnology.
Sep-14Series AEmployee Stock Option Fund$12M

Caribou Biosciences Investment Activity

Caribou Biosciences has invested in 1 company to date.

Latest investment by Caribou Biosciences was on November 18th 2014. Caribou Biosciences invested in Intellia Therapeutics in their $15M Series A round (EV/Revenue multiple of ).

See VC round multiples

Latest Investments by Caribou Biosciences

Intellia Therapeutics
Description
Intellia Therapeutics is a gene-editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. Intellia is focused on using this technology to treat genetically defined diseases. It’s evaluating multiple gene editing approaches using in vivo and ex vivo therapies to address diseases with high unmet medical needs, including ATTR amyloidosis, hereditary angioedema, sickle cell disease, and immuno-oncology. Intellia has formed collaborations with several companies to advance its pipeline, including narrow-moat Regeneron and wide-moat Novartis.
HQ CountryUnited States
HQ City
Deal Date18 Nov 2014
RoundSeries A
Raised$15M
InvestorsAtlas Venture; Caribou Biosciences; Novartis
Valuationundisclosed
EV/Revenue
EV/EBITDA

This data is available for Pro users. Sign up to see all Caribou Biosciences investments and their VC round multiples.

Start Free Trial

Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples

Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.

Start Free Trial

About Caribou Biosciences

When was Caribou Biosciences founded?Caribou Biosciences was founded in 2011.
Where is Caribou Biosciences headquartered?Caribou Biosciences is headquartered in United States.
How many employees does Caribou Biosciences have?As of today, Caribou Biosciences has over 147 employees.
Who is the CEO of Caribou Biosciences?Caribou Biosciences' CEO is Rachel Haurwitz.
Is Caribou Biosciences publicly listed?Yes, Caribou Biosciences is a public company listed on Nasdaq.
What is the stock symbol of Caribou Biosciences?Caribou Biosciences trades under CRBU ticker.
When did Caribou Biosciences go public?Caribou Biosciences went public in 2021.
Who are competitors of Caribou Biosciences?Caribou Biosciences main competitors include Context Therapeutics, Precision BioSciences, MediWound, Elicio Therapeutics, Sol-Gel Technologies, Keros Therapeutics, Binex, Atrium Therapeutics, Silence Therapeutics, Pyridam Farma.
What is the current market cap of Caribou Biosciences?Caribou Biosciences' current market cap is $212M.
What is the current revenue of Caribou Biosciences?Caribou Biosciences' last 12 months revenue is $16M.
What is the current revenue growth of Caribou Biosciences?Caribou Biosciences revenue growth (NTM/LTM) is 58%.
What is the current EV/Revenue multiple of Caribou Biosciences?Current revenue multiple of Caribou Biosciences is 7.7x.
Is Caribou Biosciences profitable?No, Caribou Biosciences is not profitable.
What is the current EBITDA of Caribou Biosciences?Caribou Biosciences has negative EBITDA and is not profitable.
What is Caribou Biosciences' EBITDA margin?Caribou Biosciences' last 12 months EBITDA margin is (889%).
What is the current EV/EBITDA multiple of Caribou Biosciences?Current EBITDA multiple of Caribou Biosciences is (0.9x).
How many companies Caribou Biosciences has acquired to date?Caribou Biosciences hasn't acquired any companies yet (or none have been disclosed publicly).
In how many companies Caribou Biosciences has invested to date?As of May 2026, Caribou Biosciences has invested in 1 company.
What was the last Caribou Biosciences investment?On 18th November 2014 Caribou Biosciences invested in Intellia Therapeutics, participating in a $15M Series A round, alongside Atlas Venture and Novartis.
In what companies Caribou Biosciences invested in?Caribou Biosciences invested in Intellia Therapeutics.

See public comps similar to Caribou Biosciences

Lists including Caribou Biosciences

Start Your
Free Trial Today

Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.

Start Trial